Low-molecular-weight heparin and abciximab for thrombo-occlusive saphenous vein graft disease. Report of 2 cases.
AUTOR(ES)
Yaryura, R
RESUMO
Both reoperation and alternative treatments for thrombo-occlusive disease of saphenous vein grafts have been fraught with a high rate of complications and a low rate of long-term success. We report 2 cases in which thrombo-occlusive saphenous vein graft disease was treated with the aid of abciximab during the intervention and with low-molecular-weight heparin for 7 to 12 days in an outpatient setting.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=325487Documentos Relacionados
- Delivery of therapeutic levels of heparin and low-molecular-weight heparin through a pulmonary route
- LOW-MOLECULAR-WEIGHT RHEUMATOID FACTOR*
- Evidence for a low-molecular-weight collagen precursor.
- Low-molecular-weight xylanase from Trichoderma viride.
- Pulmonary embolism in patients with COVID-19 and its treatment based on low-molecular-weight heparin
